DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Myelodysplastic Syndrome - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Myelodysplastic Syndrome (69)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include myelodysplastic syndrome. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 69   Next >>

Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from Denmark on 2012-08-14

Patient:

Reactions: Transplant Failure, Cardiac Failure, Myelodysplastic Syndrome, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Etoposide
    Indication: Mantle Cell Lymphoma

Melphalan Hydrochloride
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Indication: Mantle Cell Lymphoma

Vincristine
    Indication: Mantle Cell Lymphoma

Prednisolone
    Indication: Mantle Cell Lymphoma

Cytarabine
    Indication: Mantle Cell Lymphoma

Carmustine
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Indication: Mantle Cell Lymphoma

Mabthera
    Indication: Mantle Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from Denmark on 2012-08-09

Patient:

Reactions: Myelodysplastic Syndrome

Drug(s) suspected as cause:
Cyclophosphamide

Vincristine
    Dosage: day 1; cycle 5

Prednisolone
    Dosage: on days 1-5; cycle 1
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: in cycle 6 on day 9

Melphalan Hydrochloride
    Dosage: day 6; beam/c regimen
    Indication: Mantle Cell Lymphoma

Cyclophosphamide

Prednisolone
    Dosage: on days 1-5; cycle 5

Doxorubicin Hydrochloride

Cyclophosphamide
    Dosage: day 1; cycle 3
    Indication: Mantle Cell Lymphoma

Cytarabine
    Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 2

Cytarabine

Etoposide
    Dosage: on days 2-5; beam/c regimen
    Indication: Mantle Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: day 1; cycle 3
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: day 1; cycle 1

Cytarabine
    Dosage: 3 or 2 g/m2, four-3 hour infusions;cycle 6

Rituximab
    Dosage: given from cycle 5

Cyclophosphamide
    Dosage: day 1; cycle 5

Prednisolone

Cytarabine
    Dosage: 3 or 2 g/m2, four-3 hour infusions;cycle 4
    Indication: Mantle Cell Lymphoma

Doxorubicin Hydrochloride

Rituximab
    Dosage: given on day 1 from cycle 4
    Indication: Mantle Cell Lymphoma

Carmustine
    Dosage: on day 1; beam/c regimen
    Indication: Mantle Cell Lymphoma



Possible Vincristine side effects in 46 year old female

Reported by a individual with unspecified qualification from United States on 2012-08-08

Patient: 46 year old female

Reactions: Dyspnoea, Pain in Extremity, Myelodysplastic Syndrome, General Physical Health Deterioration, Pyrexia, Pulmonary Haemorrhage, Zygomycosis, Diarrhoea, Skin Discolouration, Central Nervous System Infection, Small Intestinal Haemorrhage, Cough

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: 400 ug, intravenous, every two months
    Indication: Diffuse Large B-Cell Lymphoma

Melphalan (Melphalan) (Melphalen)
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab (Rituximab) (Rituximab)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Idarubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Melphalan Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Cytarabine
    Indication: Diffuse Large B-Cell Lymphoma

Carmustine
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Carmustine
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab (Rituximab) (Rituximab)
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-01

Patient: female

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Bicnu
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Alkeran
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Dexamethasone
    Indication: Multiple Myeloma
    Start date: 2004-01-01
    End date: 2008-01-01

Cyclophosphamide
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Vepesid
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Dexamethasone
    Start date: 2008-04-08
    End date: 2008-09-01

Prednisone
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Vincristine
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Velcade
    Indication: Multiple Myeloma
    Start date: 2008-04-08
    End date: 2008-06-01

Doxorubicin Hydrochloride
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01



Possible Vincristine side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-01

Patient: female

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Velcade
    Indication: Multiple Myeloma
    Start date: 2008-04-08
    End date: 2008-09-01

Dexamethasone
    Start date: 2008-04-08

Bicnu
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Doxorubicin Hydrochloride
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Cyclophosphamide
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Dexamethasone
    Start date: 2008-06-01
    End date: 2008-01-01

Prednisone
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Vincristine
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Alkeran
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01

Dexamethasone
    Indication: Multiple Myeloma
    Start date: 2008-05-05

Dexamethasone
    Start date: 2008-05-19

Vepesid
    Indication: Multiple Myeloma
    Start date: 2000-01-01
    End date: 2000-01-01



Possible Vincristine side effects in male

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-07-30

Patient: male

Reactions: Myelodysplastic Syndrome, Azotaemia

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin Hydrochloride
    Dosage: 380 mg
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2007-03-13
    End date: 2007-05-17

Zevalin
    Dosage: 1.6 mg
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2007-07-19
    End date: 2007-07-19

Vincristine
    Dosage: 8 mg
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2007-03-13
    End date: 2007-05-17

Cyclophosphamide
    Dosage: 5700 mg
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2007-03-13
    End date: 2007-05-17



Possible Vincristine side effects in

Reported by a physician from United States on 2012-06-26

Patient:

Reactions: Death, Neoplasm Malignant, Burkitt's Lymphoma Recurrent, Myelodysplastic Syndrome, Burkitt's Leukaemia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Acute Lymphocytic Leukaemia

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Indication: Burkitt's Lymphoma

Dexamethasone
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Unknown Medication



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-22

Patient:

Reactions: Myelodysplastic Syndrome, Mantle Cell Lymphoma

Drug(s) suspected as cause:
Rituximab
    Dosage: before chemotherapy

Cytarabine
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: again 7 days later
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Prednisone TAB
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Methotrexate
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: on days plus 1 and plus 8 after asct

Rituximab
    Dosage: 4 cycle of induction therapy

Dexamethasone
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-12

Patient:

Reactions: Myelodysplastic Syndrome, Mantle Cell Lymphoma

Drug(s) suspected as cause:
Prednisone
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: again 7 days later
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: before chemotherapy

Methotrexate
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: 4 cycle of induction therapy

Cytarabine
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma

Dexamethasone
    Dosage: 4 cycle of induction therapy
    Indication: Mantle Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-06-12

Patient:

Reactions: Death, Burkitt's Lymphoma Recurrent, Neoplasm Malignant, Myelodysplastic Syndrome, Burkitt's Leukaemia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Burkitt's Lymphoma

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Monoclonal Antibodies
    Dosage: standard dose
    Indication: Acute Lymphocytic Leukaemia

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
    Indication: Burkitt's Lymphoma

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Unknown Medication



Possible Vincristine side effects in

Reported by a physician from Germany on 2012-06-01

Patient:

Reactions: Respiratory Disorder, Pain, Myelodysplastic Syndrome, Pyrexia, Neoplasm, Death, Completed Suicide, Thrombocytopenia, Vomiting, Nausea, Anaemia, Acute Myeloid Leukaemia, Toxicity To Various Agents, Haematotoxicity, Hodgkin's Disease, Mucosal Inflammation, Accident, Alopecia, Gastrointestinal Disorder, Nervous System Disorder, non-Hodgkin's Lymphoma, Cardiovascular Disorder, Leukopenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Hodgkin's Disease

Etoposide
    Indication: Hodgkin's Disease

Vincristine
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Indication: Hodgkin's Disease

Prednisone TAB
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Indication: Hodgkin's Disease

Other drugs received by patient: Radiotherapy



Possible Vincristine side effects in 55 year old female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-05-31

Patient: 55 year old female

Reactions: Myelodysplastic Syndrome, Pancytopenia, Anaemia Megaloblastic

Drug(s) suspected as cause:
Methotrexate
    Dosage: 15 mg, weekly
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 2- 3 mg, monthly
    Indication: Acute Lymphocytic Leukaemia

Daunorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Dosage: 50 mg, udaily
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in 66 year old female

Reported by a physician from United States on 2012-05-25

Patient: 66 year old female

Reactions: Refractory Anaemia With AN Excess of Blasts, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Bone Marrow Toxicity

Adverse event resulted in: death

Drug(s) suspected as cause:
Temozolomide
    Indication: Oligodendroglioma

Lomustine
    Indication: Oligodendroglioma

Carmustine
    Indication: Oligodendroglioma

Procarbazine Hydrochloride
    Indication: Oligodendroglioma

Vincristine
    Indication: Oligodendroglioma



Possible Vincristine side effects in 11 year old male

Reported by a physician from United States on 2012-05-24

Patient: 11 year old male

Reactions: Myelodysplastic Syndrome, Treatment Related Secondary Malignancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Temozolomide
    Indication: Brain Neoplasm

Etoposide
    Indication: Brain Neoplasm

Procarbazine Hydrochloride
    Indication: Brain Neoplasm

Cyclophosphamide
    Indication: Brain Neoplasm

Cisplatin
    Indication: Brain Neoplasm

Carboplatin
    Indication: Brain Neoplasm

Vincristine
    Indication: Brain Neoplasm



Possible Vincristine side effects in 70 year old female

Reported by a physician from Japan on 2012-05-11

Patient: 70 year old female

Reactions: Myelodysplastic Syndrome

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Mabthera
    Dosage: unknown
    Indication: Product Used FOR Unknown Indication

Ibritumomab Tiuxetan
    Dosage: unknown
    Indication: Product Used FOR Unknown Indication
    Start date: 2009-04-08

Cladribine
    Dosage: unknown
    Indication: Product Used FOR Unknown Indication

Mitoxantrone
    Dosage: unknown
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Dosage: unknown
    Indication: Product Used FOR Unknown Indication

Doxorubicin Hydrochloride
    Dosage: unknown
    Indication: Product Used FOR Unknown Indication

Vincristine
    Dosage: unknown
    Indication: Product Used FOR Unknown Indication

Prednisolone
    Dosage: unknown
    Indication: Product Used FOR Unknown Indication



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-10

Patient:

Reactions: Lung Neoplasm Malignant, Myelodysplastic Syndrome

Drug(s) suspected as cause:
Cyclophosphamide

Cladribine
    Indication: Chronic Lymphocytic Leukaemia Recurrent

Prednisone TAB
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia

Radiation Therapy NOS
    Indication: Chronic Lymphocytic Leukaemia

Doxorubicin HCL
    Indication: Chronic Lymphocytic Leukaemia

Granulocyte Colony Stimulating Factor
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: on 2 successive days

Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Fludarabine Phosphate
    Indication: Chronic Lymphocytic Leukaemia

Vincristine
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Indication: Chronic Lymphocytic Leukaemia Recurrent

Other drugs received by patient: Valacyclovir Hydrochloride; Acyclovir; Cotrim; Blood Products



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-10

Patient:

Reactions: Myelodysplastic Syndrome

Drug(s) suspected as cause:
Fludarabine Phosphate
    Indication: Chronic Lymphocytic Leukaemia

Granulocyte Colony Stimulating Factor
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Prednisone TAB
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia

Doxorubicin HCL
    Indication: Chronic Lymphocytic Leukaemia

Vincristine
    Indication: Chronic Lymphocytic Leukaemia

Other drugs received by patient: Valacyclovir Hydrochloride; Acyclovir; Cotrim; Blood Product



Possible Vincristine side effects in

Reported by a individual with unspecified qualification from United States on 2012-05-09

Patient:

Reactions: Death, Metastasis, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Haematotoxicity

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Indication: non-Hodgkin's Lymphoma

Mabthera
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Indication: non-Hodgkin's Lymphoma



Possible Vincristine side effects in 66 year old female

Reported by a individual with unspecified qualification from Japan on 2012-05-08

Patient: 66 year old female

Reactions: White Blood Cell Count Decreased, Platelet Count Decreased, Myelodysplastic Syndrome

Drug(s) suspected as cause:
Mabthera
    Dosage: 250 mg/m2, single
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Indication: Product Used FOR Unknown Indication

Prednisolone
    Indication: Product Used FOR Unknown Indication

Mitoxantrone Hydrochloride
    Indication: Product Used FOR Unknown Indication

Ibritumomab Tiuxetan
    Dosage: 130 mbq, single

Vincristine
    Indication: Product Used FOR Unknown Indication

Cladribine
    Indication: Product Used FOR Unknown Indication

Ibritumomab Tiuxetan
    Dosage: 11.1 mbq/kg, unk
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: Product Used FOR Unknown Indication

Other drugs received by patient: Adona; Mucosta; Basen; Acetaminophen; Amaryl; Losartan Potassium; Allegra



Possible Vincristine side effects in 54 year old male

Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-24

Patient: 54 year old male

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Adverse event resulted in: death

Drug(s) suspected as cause:
Prednisolone
    Dosage: unk
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: 200 mg/m2, for 3 conseq.days, q 28 days x 6 cycles
    Indication: Chronic Lymphocytic Leukaemia

Fludarabine Phosphate
    Dosage: 25 mg/m2, for 3 conseq. days, q 28 days x 6 cycles
    Indication: Chronic Lymphocytic Leukaemia

Mitoxantrone
    Dosage: unk
    Indication: Chronic Lymphocytic Leukaemia

Adriamycin PFS
    Dosage: unk
    Indication: Chronic Lymphocytic Leukaemia

Dexamethasone
    Dosage: unk
    Indication: Chronic Lymphocytic Leukaemia

Vincristine
    Dosage: unknown
    Indication: Chemotherapy



Possible Vincristine side effects in

Reported by a physician from United States on 2012-04-24

Patient:

Reactions: Death, B-Cell Lymphoma, Neoplasm Malignant, Acute Myeloid Leukaemia, Adverse Event, Myelodysplastic Syndrome, Haematotoxicity

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: for 5 days at 3 week interval
    Indication: B-Cell Lymphoma

Tositumomab
    Dosage: for 5 days at 3 week interval
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: for 5 days at 3 week interval
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: for 5 days at 3 week interval
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: for 5 days at 3 week interval
    Indication: B-Cell Lymphoma

Tositumomab-Iodine 131
    Dosage: dosimetric
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: for 5 days at 3 week interval
    Indication: B-Cell Lymphoma

Tositumomab-Iodine 131
    Dosage: therapeutic



Possible Vincristine side effects in 57 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-24

Patient: 57 year old male

Reactions: Stem Cell Transplant, Dyspnoea, T-Cell Type Acute Leukaemia, Acquired Diaphragmatic Eventration, Hairy Cell Leukaemia, Myelodysplastic Syndrome, Pleural Effusion, Leukaemia Recurrent, Treatment Related Secondary Malignancy

Drug(s) suspected as cause:
Dexamethasone
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2009-01-01
    End date: 2009-01-01

Adriamycin PFS
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2009-01-01
    End date: 2009-01-01

Cyclophosphamide
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2009-01-01
    End date: 2009-01-01

Vincristine
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2009-01-01
    End date: 2009-01-01

Cladribine
    Indication: Hairy Cell Leukaemia
    Start date: 2005-01-01
    End date: 2005-01-01

Cladribine
    Indication: Hairy Cell Leukaemia
    Start date: 2009-01-01
    End date: 2009-01-01



Possible Vincristine side effects in 49 year old female

Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-24

Patient: 49 year old female

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Adverse event resulted in: death

Drug(s) suspected as cause:
Prednisolone
    Dosage: unk
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: 200 mg/m2, for 3 conseq.days, q 28 days x 6 cycles
    Indication: Chronic Lymphocytic Leukaemia

Adriamycin PFS
    Dosage: unk
    Indication: Chronic Lymphocytic Leukaemia

Fludarabine Phosphate
    Dosage: 25 mg/m2, for 3 conseq. days, q 28 days x 6 cycles
    Indication: Chronic Lymphocytic Leukaemia

Vincristine
    Dosage: unk
    Indication: Chronic Lymphocytic Leukaemia



Possible Vincristine side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-17

Patient: male

Reactions: Myelodysplastic Syndrome

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin HCL

Bleomycin Sulfate

Etoposide

Cyclophosphamide

Cyclophosphamide

Vincristine

Vincristine

Vincristine

Procarbazine Hydrochloride
    Administration route: Oral

Procarbazine Hydrochloride
    Administration route: Oral

Doxorubicin HCL

Bleomycin Sulfate

Etoposide

Cyclophosphamide

Vincristine

Vincristine

Prednisone TAB
    Administration route: Oral

Bleomycin Sulfate

Etoposide

Vincristine

Procarbazine Hydrochloride
    Administration route: Oral
    Indication: Hodgkin's Disease Stage III

Procarbazine Hydrochloride
    Administration route: Oral

Doxorubicin HCL

Bleomycin Sulfate

Bleomycin Sulfate

Vincristine

Procarbazine Hydrochloride
    Administration route: Oral

Procarbazine Hydrochloride
    Administration route: Oral

Doxorubicin HCL
    Indication: Hodgkin's Disease Stage III

Doxorubicin HCL

Doxorubicin HCL

Etoposide

Cyclophosphamide

Prednisone TAB
    Administration route: Oral
    Indication: Hodgkin's Disease Stage III

Prednisone TAB
    Administration route: Oral

Procarbazine Hydrochloride
    Administration route: Oral

Radiotherapy
    Indication: Hodgkin's Disease Stage III

Doxorubicin HCL

Bleomycin Sulfate
    Indication: Hodgkin's Disease Stage III

Bleomycin Sulfate

Bleomycin Sulfate

Etoposide
    Indication: Hodgkin's Disease Stage III

Etoposide

Cyclophosphamide
    Indication: Hodgkin's Disease Stage III

Cyclophosphamide

Prednisone TAB
    Administration route: Oral

Prednisone TAB
    Administration route: Oral

Etoposide

Prednisone TAB
    Administration route: Oral

Doxorubicin HCL

Etoposide

Cyclophosphamide

Cyclophosphamide

Vincristine
    Indication: Hodgkin's Disease Stage III

Prednisone TAB
    Administration route: Oral

Prednisone TAB
    Administration route: Oral

Procarbazine Hydrochloride
    Administration route: Oral

Other drugs received by patient: Neupogen



Possible Vincristine side effects in 49 year old female

Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-16

Patient: 49 year old female

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Drug(s) suspected as cause:
Fludarabine Phosphate
    Dosage: 25 mg/m2, intravenous (not otherwise specified)
    Indication: Chronic Lymphocytic Leukaemia Stage 2

Cyclophosphamide
    Dosage: 200 mg/m2, intravenous (not otherwise specified)
    Indication: Chronic Lymphocytic Leukaemia Stage 2

Vincristine
    Indication: Chronic Lymphocytic Leukaemia Stage 2

Adriamycin PFS
    Indication: Chronic Lymphocytic Leukaemia Stage 2

Prednisolone
    Indication: Chronic Lymphocytic Leukaemia Stage 2



Possible Vincristine side effects in 54 year old male

Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-16

Patient: 54 year old male

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Drug(s) suspected as cause:
Adriamycin PFS
    Indication: Chronic Lymphocytic Leukaemia Stage 3

Vincristine
    Indication: Chronic Lymphocytic Leukaemia Stage 3

Dexamethasone
    Indication: Chronic Lymphocytic Leukaemia Stage 3

Prednisolone
    Indication: Chronic Lymphocytic Leukaemia Stage 3

Fludarabine Phosphate
    Dosage: 25 mg/m2, intravenous (not otherwise specified)
    Indication: Chronic Lymphocytic Leukaemia Stage 3

Mitoxantrone
    Indication: Chronic Lymphocytic Leukaemia Stage 3

Cyclophosphamide
    Dosage: 200 mg/m2, intravenous (not otherwise specified)
    Indication: Chronic Lymphocytic Leukaemia Stage 3



Possible Vincristine side effects in 54 year old male

Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-13

Patient: 54 year old male

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Adverse event resulted in: death

Drug(s) suspected as cause:
Mitoxantrone
    Indication: Chronic Lymphocytic Leukaemia

Dexamethasone
    Indication: Chronic Lymphocytic Leukaemia

Fludarabine Phosphate
    Dosage: therapy for 3 consecutive days in each 28day cycle. fnd therapy 4 cycles
    Indication: Chronic Lymphocytic Leukaemia

Prednisolone
    Indication: Chronic Lymphocytic Leukaemia

Vincristine
    Dosage: chop 2 cycles
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: therapy for 3 consecutive days in each 28day cycle.chop therapy 2 cycles
    Indication: Chronic Lymphocytic Leukaemia

Adriamycin PFS
    Dosage: chop 2 cycles
    Indication: Chronic Lymphocytic Leukaemia



Possible Vincristine side effects in 49 year old female

Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-13

Patient: 49 year old female

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Adverse event resulted in: death

Drug(s) suspected as cause:
Fludarabine Phosphate
    Dosage: therapy for 3 conescutive days in each 28day cycle.
    Indication: Chronic Lymphocytic Leukaemia

Adriamycin PFS
    Dosage: chop 6 cycles
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: therapy for 3 consecutive days in each 28day cycle.chop=6cycles
    Indication: Chronic Lymphocytic Leukaemia

Prednisolone
    Dosage: chop =6cycle
    Indication: Chronic Lymphocytic Leukaemia

Vincristine
    Dosage: chop 6 cycles
    Indication: Chronic Lymphocytic Leukaemia



Possible Vincristine side effects in 54 year old male

Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-04

Patient: 54 year old male

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Drug(s) suspected as cause:
Cyclophosphamide

Fludarabine Phosphate

Mitoxantrone

Dexamethasone

Prednisolone

Cyclophosphamide

Fludarabine Phosphate

Adriamycin PFS

Vincristine



Possible Vincristine side effects in 54 year old male

Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-04

Patient: 54 year old male

Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome

Drug(s) suspected as cause:
Prednisolone
    Indication: Chronic Lymphocytic Leukaemia

Vincristine
    Indication: Chronic Lymphocytic Leukaemia

Adriamycin PFS
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: 200 mg/meter square
    Indication: Chronic Lymphocytic Leukaemia

Mitoxantrone
    Indication: Chronic Lymphocytic Leukaemia

Fludarabine Phosphate
    Dosage: 25 mg/meter square
    Indication: Chronic Lymphocytic Leukaemia

Dexamethasone
    Indication: Chronic Lymphocytic Leukaemia



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017